What is CerFlux?
CerFlux specializes in personalized medicine technology designed to match cancer treatments to individual tumors, ensuring effective therapeutic interventions from the outset. Their flagship innovation, the Personalized Oncology Efficacy Test (POET), enables the simultaneous screening of multiple therapy agents on biopsy tissue. This comprehensive approach identifies the most effective treatment options within a week, addressing the critical need for personalized cancer treatment and mitigating the risks associated with ineffective therapies and their associated costs. CerFlux's platform serves a broad spectrum of stakeholders, including patients, healthcare providers, payors, and pharmaceutical companies, all united in the fight against cancer.
How much funding has CerFlux raised?
CerFlux has raised a total of $1M across 1 funding round:
Angel/Seed
$1M
Angel/Seed (2021): $1M, investors not publicly disclosed
What's next for CerFlux?
With the recent major strategic investment, CerFlux is poised for significant expansion and further development of its POET technology. This capital infusion is anticipated to fuel advancements in clinical validation, market penetration, and the scaling of operations. The company's focus on personalized oncology aligns with the growing trend in healthcare towards precision medicine, positioning CerFlux for substantial growth and impact in the competitive biotech landscape. Future strategic initiatives will likely involve forging deeper partnerships within the healthcare ecosystem and expanding the application of their diagnostic platform to a wider range of cancer types.
See full CerFlux company page
